Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade

Assay and Drug Development Technologies
Khuram W ChaudharyAnthony Bahinski

Abstract

Inhibition of the delayed-rectifier potassium channel current, human ether-a-go-go (hERG), by pharmaceutical agents can lead to acquired long QT syndrome and the generation of potentially lethal arrhythmias and sudden death. There remains an unmet need for higher-throughput assays to screen compounds in preclinical development for the potential to block hERG and cause QT prolongation. We evaluated the rubidium efflux assay for its ability to determine block of the hERG potassium channel. hERG-transfected human embryonic kidney-293 cells were cultured on 96-well assay plates and loaded with rubidium ion by incubating in media in which potassium was replaced by 5.4 mM Rb+. Cells were exposed to test compounds and then depolarized with a K+ channel opening buffer containing 50 mM K+. The supernatant was removed, and cells were lysed using 0.1% Triton X-100. Concentration-response curves were generated for test agents by determining the Rb+ efflux using a flame atomic absorption spectrometer. Multiple trials with cisapride yielded 50% inhibitory concentration values between 308.1 +/- 11 nM to 456.3 +/- 24 nM for inhibition of Rb+ efflux and a Z factor of 0.80 +/- 0.07 (n = 5 plates, 12 wells per plate). The values for inhibition of...Continue Reading

References

Sep 7, 1976·Biochemical and Biophysical Research Communications·J Garcia-MartinezE Garcia-Peregrin
Aug 1, 1979·The Journal of General Physiology·S S Miller, R H Steinberg
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·M B BacanerR M Brochu
Jan 1, 1982·The Journal of Membrane Biology·S S Miller, R H Steinberg
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·J W Warmke, B Ganetzky
Apr 1, 1997·Cardiovascular Drugs and Therapy·L A Nair, A O Grant
Jun 6, 2000·Journal of Biomolecular Screening·J H ZhangK R Oldenburg
Jun 15, 2000·European Journal of Clinical Pharmacology·F De PontiN Montanaro
Jun 27, 2000·Journal of Cardiovascular Electrophysiology·M C Sanguinetti
Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·J S MitchesonM C Sanguinetti
Feb 13, 2001·Drug Discovery Today·R NetzerO Pongs
Nov 2, 2001·Journal of Biomolecular Screening·W TangT Garyantes
Mar 22, 2002·Pflügers Archiv : European journal of physiology·Manjula WeerapuraStanley Nattel
Apr 3, 2002·Drug Development and Industrial Pharmacy·Charles S ChengWeifeng Yu
Apr 19, 2002·The Journal of Biological Chemistry·Jose A Sánchez-ChapulaMichael C Sanguinetti
May 8, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Fabrizio De PontiNicola Montanaro
Aug 15, 2002·European Journal of Pharmacology·Sathapana KongsamutDavid Rampe
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
May 2, 2003·Nature·Fred J Sigworth
May 2, 2003·Nature·Youxing JiangRoderick MacKinnon
Oct 28, 2003·The Journal of Biological Chemistry·Niels DecherMichael C Sanguinetti
Dec 31, 2003·The Journal of Biological Chemistry·David FernandezMichael C Sanguinetti
Apr 20, 2004·Assay and Drug Development Technologies·Sikander GillDong Liang
Apr 28, 2004·Cell Calcium·A M Brown
Jul 15, 2004·Toxicology in Vitro : an International Journal Published in Association with BIBRA·R HamidP Bullock
Jul 24, 2004·Journal of Pharmacological Sciences·Peter J S ChiuRichard Mitchell
Sep 24, 2004·Journal of Pharmacological and Toxicological Methods·Glenn E KirschArthur M Brown
Mar 31, 2005·Assay and Drug Development Technologies·Steve SorotaTony Priestley

❮ Previous
Next ❯

Citations

Jun 6, 2007·Journal of Computer-aided Molecular Design·David J Diller, Doug W Hobbs
Jul 24, 2007·Nature Reviews. Drug Discovery·Jeffrey A KramerDale L Morris
Mar 24, 2011·Future Medicinal Chemistry·Georg C TerstappenRavikumar Peri
Dec 15, 2015·Acta Pharmacologica Sinica·Hai-bo YuXiao-liang Wang
Jan 3, 2016·Drug Discovery Today. Technologies·Beiyan Zou
Jul 12, 2008·Pharmacology & Therapeutics·Jules C HancoxYi Hong Zhang
Apr 30, 2015·Future Medicinal Chemistry·Yankang JingIstvan J Enyedy
Jun 8, 2013·Current Protocols in Pharmacology·Claire Townsend, Barry S Brown
Dec 16, 2011·The Journal of Pharmacology and Experimental Therapeutics·B BitonP Avenet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.